SECFilings News & Analysis

6 articles

Market Mood

0 Bullish6 Neutral0 Bearish
Edwards Lifesciences Corp (EW) Form 4 Filing on July 30
TechNeutral7/30/2026

Edwards Lifesciences Corp (EW) Form 4 Filing on July 30

Edwards Lifesciences Corp (EW) filed a Form 4, an official statement regarding insider transactions, which is scheduled for July 30. This filing typically includes details on the buying or selling of shares by company executives or board members. Such disclosures are essential as they provide transparency regarding insider activities that may influence investor sentiment. Monitoring Form 4 filings helps investors gauge company insiders' confidence in the company’s future performance.

Read More: Edwards Lifesciences Corp (EW) Form 4 Filing on July 30
Remitly Global (RELY) Form 4 Filed on July 17, 2023
MarketsNeutral7/17/2026

Remitly Global (RELY) Form 4 Filed on July 17, 2023

Remitly Global Inc filed a Form 4 on July 17, 2023. This regulatory filing typically reports insider transactions, detailing stock purchases or sales by company executives or board members. Such filings can signal insiders' confidence or lack thereof in the company's future performance. Investors may find this information indicative of potential shifts in the stock's valuation, making it important for market sentiment regarding Remitly Global (RELY).

Read More: Remitly Global (RELY) Form 4 Filed on July 17, 2023
First Internet Bancorp Announces DEF 14A Filing for March 27 Meeting
EarningsNeutral3/27/2026

First Internet Bancorp Announces DEF 14A Filing for March 27 Meeting

First Internet Bancorp has filed its DEF 14A with the SEC, detailing information for the upcoming shareholder meeting on March 27. This includes critical information about executive compensation, board nominations, and shareholder proposals. The filing is a requirement for publicly traded companies ahead of annual meetings, and its details can significantly influence shareholder voting and company governance practices. Such filings are important for market participants assessing corporate governance and transparency.

Read More: First Internet Bancorp Announces DEF 14A Filing for March 27 Meeting
Universal Safety Products Files Form 13D/A on 23 March 2023
EarningsNeutral3/23/2026

Universal Safety Products Files Form 13D/A on 23 March 2023

Universal Safety Products submitted Form 13D/A, disclosing ownership updates and shareholder information as of March 23, 2023. This filing is significant as it provides insights into the company's investor base and potential changes in control or strategic direction. Such disclosures can influence shareholder sentiment and market perception, potentially impacting stock price movements. Shareholder events like these are closely monitored by investors for their implications on governance and investment strategies.

Read More: Universal Safety Products Files Form 13D/A on 23 March 2023
CSW Industrials Reports SEC Form 144 Filing on March 23, 2023
EarningsNeutral3/23/2026

CSW Industrials Reports SEC Form 144 Filing on March 23, 2023

CSW Industrials filed Form 144 with the SEC on March 23, 2023. This form indicates the intent to sell shares amounting to a specified number, usually associated with individuals or groups intending to sell restricted or control securities. Such filings can signal market movements and impact trading volume and share price of the company. The specifics of the number of shares or the value involved were not detailed in the source.

Read More: CSW Industrials Reports SEC Form 144 Filing on March 23, 2023
RTW Investments Acquires $192.59 Million Stake in Apellis Pharmaceuticals
EarningsNeutral3/21/2026

RTW Investments Acquires $192.59 Million Stake in Apellis Pharmaceuticals

RTW Investments has initiated a new stake in Apellis Pharmaceuticals (NASDAQ: APLS) by acquiring 7,666,764 shares worth $192.59 million, according to a February 17, 2026, SEC filing. Apellis reported a total revenue of approximately $689 million last year, with a market capitalization of $2.2 billion. The stock is currently priced at $17.21, reflecting a 29% decline over the past year, underperforming the S&P 500's 15% increase. This significant investment in Apellis, which produces treatments for rare diseases, could influence market perceptions of biotech investments.

Read More: RTW Investments Acquires $192.59 Million Stake in Apellis Pharmaceuticals